Department of Pathology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
Department of General Surgery, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey.
J Coll Physicians Surg Pak. 2022 Sep;32(9):1196-1201. doi: 10.29271/jcpsp.2022.09.1196.
To evaluate whether there are differences in invasive micropapillary carcinoma (IMPC) and invasive ductal carcinoma-NOS (IDC-NOS) according to the clinicopathological features and prognosis including molecular subtypes.
Descriptive study.
Department of Pathology, University of Health Sciences, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey, from 2003 to 2016.
Operated breast cancer cases (58 IMPC + 326 IDC-NOS), with long-term follow-up findings (cases followed up until 2020), were reviewed. The cases, whose other component was only IDC-NOS, were included in the mixed IMPC group. The clinical features, including clinical presentation, treatments, and follow-up information were obtained from the patient clinical database. The IMPC cases included in the study were re-examined, and micropapillary tumour components were confirmed based on the criteria set by the World Health Organisation (WHO). The clinicopathological findings, recurrence, and survival data of both groups were compared. In addition, IDC-NOS was divided into the molecular subgroups and compared with IMPC cases in terms of 5-year overall survival (OS).
There was no significant difference between the two groups for the distribution of molecular subtypes. There was a statistically significant difference among the nuclear grade, tumour size, nodal status, lymphovascular, and perineural invasion. In the first 5-year period, the OS rate for IDC-NOS and IMPC was 90.8% and 86.2% (p<0.05). The 5-year OS rate of luminal A, luminal B, HER2, triple negative (TN), and IMPC patients was 97.6%, 91.3%, 90%, 70%, and 86.2%, respectively (p<0.05). The OS rate in patients with TN and IMPC was similar which was found significantly lower than the other groups (luminal A, luminal B, and HER2). The median OS was 51.3 months and 53.9 months for the patients with TN and IMPC, respectively (p<0.001). This difference disappeared in the 10th and 15th years of follow-up.
The majority of the deaths in IMPC occurred within the first 5 years. The 5-year OS rates were similar in the TN and IMPC patients. The survival pattern of IMPC is parallel with TN, Therefore, clinical, therapeutic, and prognostic evaluation in IMPC can be done like TN.
Invasive ductal carcinoma, Invasive micropapillary carcinoma, Survival.
评估浸润性微乳头状癌（IMPC）与浸润性导管癌-非特殊型（IDC-NOS）在临床病理特征和包括分子亚型在内的预后方面是否存在差异。
描述性研究。
土耳其伊斯坦布尔健康科学大学海达尔帕萨努梅恩培训和研究医院病理学系，2003 年至 2016 年。
回顾了长期随访结果（随访至 2020 年）的手术乳腺癌病例（58 例 IMPC+326 例 IDC-NOS）。将仅为 IDC-NOS 其他成分的病例纳入混合 IMPC 组。从患者临床数据库中获得临床特征，包括临床表现、治疗和随访信息。对纳入研究的 IMPC 病例进行重新检查，并根据世界卫生组织（WHO）设定的标准确认微乳头状肿瘤成分。比较两组的临床病理发现、复发和生存数据。此外，将 IDC-NOS 分为分子亚组，并根据 5 年总生存率（OS）与 IMPC 病例进行比较。
两组之间的分子亚型分布无显著差异。核分级、肿瘤大小、淋巴结状态、脉管和神经周围侵犯存在统计学差异。在最初的 5 年内，IDC-NOS 和 IMPC 的 OS 率分别为 90.8%和 86.2%（p<0.05）。Luminal A、Luminal B、HER2、三阴性（TN）和 IMPC 患者的 5 年 OS 率分别为 97.6%、91.3%、90%、70%和 86.2%（p<0.05）。TN 和 IMPC 患者的 OS 率相似，明显低于其他组（Luminal A、Luminal B 和 HER2）。TN 和 IMPC 患者的中位 OS 分别为 51.3 个月和 53.9 个月（p<0.001）。这种差异在第 10 年和第 15 年的随访中消失。
IMPC 患者的大多数死亡发生在最初的 5 年内。TN 和 IMPC 患者的 5 年 OS 率相似。IMPC 的生存模式与 TN 平行，因此，在 IMPC 中可以进行临床、治疗和预后评估，就像 TN 一样。
浸润性导管癌；浸润性微乳头状癌；生存
